Journal
DRUG DISCOVERY TODAY
Volume 18, Issue 3-4, Pages 110-115Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2012.08.005
Keywords
-
Categories
Funding
- FDA National Center for Toxicological Research (NCTR) through the Oak Ridge Institute for Science and Education (ORISE)
Ask authors/readers for more resources
Drug repositioning, exemplified by sildenafil and thalidomide, is a promising way to explore alternative indications for existing drugs. Recent research has shown that bioinformatics-based approaches have the potential to offer systematic insights into the complex relationships among drugs, targets and diseases necessary for successful repositioning. In this article, we propose the key bioinformatics steps essential for discovering valuable repositioning methods. The proposed steps (repurposing with a purpose, repurposing with a strategy and repurposing with confidence) are aimed at providing a repurposing pipeline, with particular focus on the proposed Drugs of New Indications (DNI) database, which can be used alongside currently available resources to improve in silico drug repositioning.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available